abstract |
(57) [Summary] [PROBLEMS] To provide use of an antibody against X3CR1 and fractalkine. SOLUTION: An anti-CX3CR1 antibody facilitates identification, removal, and separation of killer lymphocytes. Further, by suppressing the interaction between CX3CR1 and fractalkine, it becomes possible to provide an antibody drug that suppresses the migration of killer lymphocytes and suppresses the cytotoxic activity. |